Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases.

Autor:	Bousquet J; Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.; MACVIA France, University Hospital, Montpellier, France., Le Moing V; Maladies Infectiouses et Tropicales, CHU Montpellier, France., Blain H; Department of Geriatrics, Montpellier University Hospital, Montpellier, France., Czarlewski W; Medical Consulting Czarlewski, Levallois, France.; MASK-air, Montpellier, France., Zuberbier T; Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany., de la Torre R; CIBER Fisiopatologia de La Obesidad y Nutrición (CIBEROBN), Madrid, Spain.; IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Pizarro Lozano N; IMIM (Hospital del Mar Research Institute), Barcelona, Spain., Reynes J; Maladies Infectiouses et Tropicales, CHU Montpellier, France., Bedbrook A; MACVIA France, University Hospital, Montpellier, France.; MASK-air, Montpellier, France., Cristol JP; Laboratoire de Biochimie et Hormonologie, PhyMedExp, Université de Montpellier, INSERM, CNRS, CHU de Montpellier, France., Cruz AA; Fundação ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil., Fiocchi A; Division of Allergy, Department of Pediatric Medicine - The Bambino Gesù Children's Research Hospital Holy see, Rome, Italy., Haahtela T; Skin and Allergy Hospital, Helsinki University Hospital, And University of Helsinki, Helsinki, Finland., Iaccarino G; Department of Advanced Biomedical Sciences, Federico II University, Napoli, Italy., Klimek L; Center for Rhinology and Allergology, Wiesbaden, Germany., Kuna P; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland., Melén E; Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's Hospital, Stockholm, Sweden., Mullol J; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic - Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Spain., Samolinski B; Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland., Valiulis A; Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania., Anto JM; IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.; ISGlobal. ISGlobAL, Barcelona, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	The World Allergy Organization journal [World Allergy Organ J] 2020 Dec 09; Vol. 14 (1), pp. 100498. Date of Electronic Publication: 2020 Dec 09 (Print Publication: 2021).
DOI:	10.1016/j.waojou.2020.100498
Abstrakt:	COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first COVID-19 symptoms. They were found to reduce many of the symptoms rapidly and for a duration of 6-12 h by repeated dosing. When the patient was stable but still suffering from cough and nasal obstruction when not taking the broccoli capsules, a double-blind induced cough challenge confirmed the speed of onset of the capsules (less than 10 min). A second clinical case with lower broccoli doses carried out during the cytokine storm confirmed the clinical benefits already observed. A third clinical case showed similar effects at the onset of symptoms. In the first clinical trial, we used a dose of under 600 μmol per day of glucoraphanin. However, such a high dose may induce pharmacologic effects that require careful examination before the performance of any study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2-interacting nutrients are effective in COVID-19. However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety. Competing Interests: None of the authors declared any competing interest. (© 2020 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu